Abstract |
We present the second draft of a consensus-assisted protocol on the adjuvant treatment after cardiac surgery with immunoglobulins of mediastinitis. CLINICAL PHASE: Phase III. OBJECTIVE OF THE STUDY: Placebo-controlled investigation of the clinical efficacy of Pentaglobin (Biotest, Germany) as an added treatment in patients with mediastinitis. MEDICATION: DOSAGE: STUDY DESIGN: Prospective, placebo-controlled, double blind, randomised, multicentre. SAMPLE SIZE: n = 100; 50 patients with Pentaglobin (active), 50 patients with placebo. PRIMARY OUTCOME MEASURE: Cumulative therapeutic intervention scoring system (TISS-28) during hospital stay.
|
Authors | G Marggraf, E A Neugebauer |
Journal | The European journal of surgery. Supplement. : = Acta chirurgica. Supplement
(Eur J Surg Suppl)
Issue 584
Pg. 26-32
( 1999)
ISSN: 1102-416X [Print] England |
PMID | 10890228
(Publication Type: Clinical Trial, Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Anti-Bacterial Agents
- Immunoglobulin A
- Immunoglobulin M
- Immunoglobulins, Intravenous
- Placebos
- pentaglobulin
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Cardiac Surgical Procedures
(adverse effects)
- Double-Blind Method
- Follow-Up Studies
- Humans
- Immunoglobulin A
(therapeutic use)
- Immunoglobulin M
(therapeutic use)
- Immunoglobulins, Intravenous
(therapeutic use)
- Mediastinitis
(therapy)
- Patient Selection
- Placebos
- Prospective Studies
- Research Design
- Sample Size
- Sepsis
(therapy)
- Surgical Wound Dehiscence
(therapy)
- Surgical Wound Infection
(therapy)
- Treatment Outcome
|